Experts agree that next-generation sequencing is the best weapon for comprehensively tracking multi-drug-resistant TB
A new exome-based test will help determine the genetic variants—germline and somatic—driving these rare cancers
Data from this international partnership will assist biologists in protecting the herds they study
On Rare Disease Day 2023, Illumina spotlights four patient organizations and accelerates iHope
NysnoBio is developing a gene therapy to slow progression in people under age 50
| Date | Publication | Title |
|---|---|---|
| Nov 21, 2022 | GenomeWeb | Illumina, Al Jalila Children's Specialty Hospital Ink Rapid Whole-Genome Sequencing Deal |
| Nov 21, 2022 | CSR Wire | Q&A With the CTO: Storing Growing Data While Reducing Environmental Impact |
| Nov 12, 2022 | The National | New Dubai centre aims to shed light on genetic aspects of disease in the Middle East |
| Nov 10, 2022 | HarryGlorikian | Episode 100! Illumina’s Phil Febbo On The New Era Of Low-Cost Genome Sequencing |
| Oct 18, 2022 | GenomeWeb | Illumina, GenoScreen Partner to Comarket Genomic Testing for Multidrug-Resistant TB |
At Illumina, we push boundaries. We think beyond the conventional. We dream big. With the energy of so many bright and accomplished people, the opportunities are endless.
Search for JobsIf you are a member of the media:
If you are not a member of the media, please visit Contact Us.
